Markers of Angiogenesis in Ovarian Cancer

Tumor development and progression are inherently dependent on the process of angiogenesis. Recently, anti-angiogenic therapy has started to show promise as an effective treatment strategy in many solid tumors including ovarian carcinoma. Unfortunately, lack of effective biomarkers presents a challen...

Full description

Bibliographic Details
Main Authors: William M. Merritt, Anil K. Sood
Format: Article
Language:English
Published: Hindawi Limited 2007-01-01
Series:Disease Markers
Online Access:http://dx.doi.org/10.1155/2007/257602
id doaj-7768a84d885742e4b9855c7ed5220ce1
record_format Article
spelling doaj-7768a84d885742e4b9855c7ed5220ce12020-11-25T00:07:13ZengHindawi LimitedDisease Markers0278-02401875-86302007-01-01235-641943110.1155/2007/257602Markers of Angiogenesis in Ovarian CancerWilliam M. Merritt0Anil K. Sood1Department of Gynecologic Oncology, U.T. M.D. Anderson Cancer Center, Unit 1362, P.O. Box 301439, Houston TX 77230-1439, USADepartment of Gynecologic Oncology, U.T. M.D. Anderson Cancer Center, Unit 1362, P.O. Box 301439, Houston TX 77230-1439, USATumor development and progression are inherently dependent on the process of angiogenesis. Recently, anti-angiogenic therapy has started to show promise as an effective treatment strategy in many solid tumors including ovarian carcinoma. Unfortunately, lack of effective biomarkers presents a challenge for oncologists in treatment planning as well as monitoring response of new anti-vascular agents. Previously, quantification of angiogenesis by microvessel density analysis provided useful prognostic information, however, its utility following anti-angiogenic therapy remains to be determined. Moreover, since secreted cytokines play an active part in angiogenesis by mediating neovascularization in tumors, investigations have focused on their potential role to serve as candidate biomarkers of disease detection, prognosis, and treatment response. In this article, we review the role of key angiogenesis markers as potential biomarkers in ovarian carcinoma.http://dx.doi.org/10.1155/2007/257602
collection DOAJ
language English
format Article
sources DOAJ
author William M. Merritt
Anil K. Sood
spellingShingle William M. Merritt
Anil K. Sood
Markers of Angiogenesis in Ovarian Cancer
Disease Markers
author_facet William M. Merritt
Anil K. Sood
author_sort William M. Merritt
title Markers of Angiogenesis in Ovarian Cancer
title_short Markers of Angiogenesis in Ovarian Cancer
title_full Markers of Angiogenesis in Ovarian Cancer
title_fullStr Markers of Angiogenesis in Ovarian Cancer
title_full_unstemmed Markers of Angiogenesis in Ovarian Cancer
title_sort markers of angiogenesis in ovarian cancer
publisher Hindawi Limited
series Disease Markers
issn 0278-0240
1875-8630
publishDate 2007-01-01
description Tumor development and progression are inherently dependent on the process of angiogenesis. Recently, anti-angiogenic therapy has started to show promise as an effective treatment strategy in many solid tumors including ovarian carcinoma. Unfortunately, lack of effective biomarkers presents a challenge for oncologists in treatment planning as well as monitoring response of new anti-vascular agents. Previously, quantification of angiogenesis by microvessel density analysis provided useful prognostic information, however, its utility following anti-angiogenic therapy remains to be determined. Moreover, since secreted cytokines play an active part in angiogenesis by mediating neovascularization in tumors, investigations have focused on their potential role to serve as candidate biomarkers of disease detection, prognosis, and treatment response. In this article, we review the role of key angiogenesis markers as potential biomarkers in ovarian carcinoma.
url http://dx.doi.org/10.1155/2007/257602
work_keys_str_mv AT williammmerritt markersofangiogenesisinovariancancer
AT anilksood markersofangiogenesisinovariancancer
_version_ 1725419448793300992